Eli Lilly and Company and Incyte announced new one-year results showing once-daily oral baricitinib 4 mg helped the majority of adolescent patients with severe alopecia areata achieve successful hair regrowth on the scalp, eyebrows, and eyelashes, following earlier pivotal Phase 3 findings presented at dermatology conferences.
Severe alopecia areata is an incurable autoimmune disease in which the body’s immune system mistakenly attacks hair follicles, halting natural growth and triggering profound emotional and psychological burdens for those affected. While the condition can emerge at any age, nearly half of all individuals who develop severe disease experience symptom onset before adulthood, leaving young populations underrepresented in clinical research.
Now, fresh clinical data are changing the treatment landscape. A widely used rheumatoid arthritis medication is demonstrating a capacity to restore hair coverage in patients who have lost substantial portions of their scalp, eyebrow, and eyelash hair.
Clinical Trial Findings and Pediatric Regrowth Rates
Data from the Phase 3 BRAVE-AA-PEDS trial specifically evaluated children and adolescents aged 12 to under 18 with severe alopecia areata. At the start of the study, participants presented with an average of 89 percent scalp hair loss, with nearly two-thirds classified as having very severe disease based on Severity of Alopecia Tool scores between 95 and 100. Furthermore, 65 percent of participants exhibited minimal or no eyebrow hair, and 57 percent had minimal or no eyelash hair.
Following 52 weeks of continuous once-daily treatment, 54.1 percent of patients receiving baricitinib 4 mg and 31 percent receiving the 2 mg dose achieved successful scalp hair regrowth, defined as 80 percent or more scalp hair coverage. When examining a subset of patients with severe disease whose baseline SALT scores ranged from 50 to 94, those response rates climbed even higher, with 71 percent of adolescents on the 4 mg dose achieving successful scalp hair coverage.
Regrowth extended beyond the scalp. Among adolescents on the 4 mg dose, 64.8 percent achieved significant eyebrow regrowth, and 63.3 percent achieved eyelash regrowth at the one-year mark.
How Baricitinib Intervenes in Autoimmune Hair Loss
Baricitinib, commercially known as Olumiant, is an oral JAK inhibitor originally discovered by Incyte and licensed to Eli Lilly and Company. Unlike topical treatments that attempt to stimulate follicles from the outside, baricitinib operates internally by targeting the biological signaling pathways driving the autoimmune response.
Because JAK inhibitors have been routinely prescribed for autoimmune joint conditions like rheumatoid arthritis, many dermatologists already possess familiarity with monitoring patients and managing the medication’s safety considerations.
Adult Trials and Long-Term Sustained Efficacy
The pediatric data build upon foundational adult research from the extensive BRAVE-AA1 and BRAVE-AA2 clinical programs. In those earlier randomized trials involving a total of 1,200 people with severe alopecia areata, daily doses of baricitinib demonstrated that one-third of patients who received the larger dose grew their hair back over a 36-week period.
Final long-term results presented at the Fall Clinical Dermatology Conference indicate that high rates of regrowth are sustainable. Among adult patients with severe disease who responded to baricitinib at 52 weeks, 86.5 percent of those on the 4 mg dose and 84.7 percent on the 2 mg dose maintained successful scalp hair coverage through approximately four years of continuous treatment.
Researchers emphasized that early intervention matters significantly. A post-hoc analysis of adolescent patients diagnosed with severe alopecia areata less than two years before starting therapy showed that 80 percent of those receiving baricitinib 4 mg achieved successful hair regrowth at one year.
Safety Profile and Regulatory Next Steps
The safety profile observed in the pediatric and adult trials remained consistent, with no new safety signals identified up to five years of observation. The most frequently reported adverse events included acne, upper respiratory tract infections, and influenza. Clinical investigators noted no deaths, opportunistic infections, major adverse cardiovascular events, or venous thromboembolic events during the trial period.
Following these findings, Eli Lilly and Company intends to submit the comprehensive BRAVE-AA-PEDS clinical dataset to global regulatory authorities to seek a formal label update for baricitinib in younger populations.
